0.0897EUR+1.36%Mkt Cap: 21.03M EURP/E: —Last update: 2026-06-01
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company deve…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap21.03M EUR
Enterprise Value29.95M EUR
Revenue (TTM)652.00K EUR
Gross Profit652.00K EUR
Net Income (TTM)-12.04M EUR
Revenue/Share0.0040 EUR
Last Price0.0897 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees13
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0013183985
Valuation
P/E (Trailing)—
P/E (Forward)-0.18
PEG—
EV/EBITDA-2.73
EV/Revenue45.93
P/S31.83
P/B-0.78
EPS (TTM)-0.08
EPS (Forward)-0.50
52W Range
0.07528% of range0.2490
52W High0.2490 EUR
52W Low0.0752 EUR
Profitability
Gross Margin100.00%
Oper. Margin-705.96%
EBITDA Margin0.00%
Profit Margin-1203600.00%
ROE48.26%
ROA-145.78%
Growth
Revenue Growth-32.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.17M EUR
CapEx (TTM)4.00K EUR
FCF Margin-1110.64%
FCF Yield-34.43%
Net Debt10.45M EUR
Net Debt/EBITDA-0.95
Balance Sheet
Debt/Equity-0.52
Current Ratio0.39
Quick Ratio0.32
Book Value/Sh-0.1130 EUR
Cash/Share0.0110 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.3050 EUR
Target Range0.2100 EUR – 0.4000 EUR
# Analysts2
Ownership
Shares Out.234.47M
Float149.93M
Insiders7.07%
Institutions46.31%
Technical
SMA 500.0851 (+5.3%)
SMA 2000.1075 (-16.5%)
Beta0.61
S&P 52W Chg27.94%
Avg Vol (30d)542.60K
Avg Vol (10d)537.73K
Technical Indicators
RSI (14)56.3
MACD0.0014
MACD Signal0.0010
MACD Hist.+0.0004
BB Upper0.0924 EUR
BB Middle0.0860 EUR
BB Lower0.0797 EUR
BB Width14.75%
ATR (14)0.0032 EUR
Vol Ratio (20d)0.43x